Utility of Sodium Lactate Infusion During Septic Shock (ULIS1)
Utility of Sodium Lactate Infusion During Septic Shock: Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
ULIS-1 consists in three arms of treatment during the first 24hrs of septic shock treatment.
- normal saline
- sodium lactate 2.5ml/kg in 60min then
- either 0.25 or 0.5ml/kg/h during 24hrs Main criteria is fluid balance at 48hrs
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Raphaël Favory, MD,PhD
- Phone Number: +33 03 20 44 54 94
- Email: raphael.favory@chru-lille.fr
Study Locations
-
-
-
Arras, France
- CH Arras
-
Douai, France
- CH DOUAI
-
Dunkirk, France
- CH Dunkerque
-
Lens, France
- CH Lens
-
Lille, France
- Hôpital Roger Salengro, CHU
-
Roubaix, France
- Hopital Victor Provo - Roubaix
-
Rouen, France
- CHU Rouen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Presence of septic shock
- requiring vascular filling within 12 hours after introduction of Noradrenaline. Septic shock is defined as sepsis with persistent hypotension requiring the administration of vasopressors to maintain RTE > 65mmHg.
- social insurance
Exclusion Criteria:
- pregnancy
- cardiac arrest
- more than 50ml/kg of fluid loading
- chronic renal failure with chronic hemodialysis or the investigators estimate a need for renal replacement therapy in the following 24hrs
- child C or acute liver failure with PT<40% (unless AVK)
- plasmatic sodium <120 or >145mmol/l
- metabolic alkalosis with pH>7.45
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Sham Comparator: Normal saline
at physician discretion
|
normal saline at physician discretion
|
|
Experimental: Sodium lactate light dose
bolus 2.5ml/kg lactate 60min then 0.25ml/kg/h during 24hrs
|
bolus 2.5ml/kg then 0.25ml/kg/h
|
|
Experimental: Sodium lactate high dose
bolus 2.5ml/kg lactate 60min then 0.50ml/kg/h during 24hrs
|
bolus 2.5ml/kg then 0.5ml/kg/h
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
fluid balance
Time Frame: at 48 hours
|
fluid balance
|
at 48 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
fluid balance at day 7
Time Frame: Day 7
|
Day 7
|
|
SOFA (Sequential Organ Failure Assessment)
Time Frame: Day 1, Day 2, Day 3, Day 7
|
Day 1, Day 2, Day 3, Day 7
|
|
death in Intensive Care Unit (ICU)
Time Frame: Day 90
|
Day 90
|
|
number of patients dead
Time Frame: Day 28
|
Day 28
|
|
death in hospital
Time Frame: Day 90
|
Day 90
|
|
catecholamines free days
Time Frame: Day 28
|
Day 28
|
|
ventilator free days
Time Frame: Day 28
|
Day 28
|
|
renal replacement therapy free days
Time Frame: Day 28
|
Day 28
|
|
new kidney failure
Time Frame: Day 28
|
Day 28
|
|
nosocomial infections
Time Frame: day 90
|
day 90
|
|
hypernatremia
Time Frame: Day 2
|
Day 2
|
|
hypokaliemia
Time Frame: Day 2
|
Day 2
|
|
metabolic alkalosis
Time Frame: day 2
|
day 2
|
|
hemodynamic effects assessed by the PICCO® monitoring system
Time Frame: at 48 hours
|
at 48 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Raphaël Favory, MD,PhD, University Hospital, Lille
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Shock
- Pathological Conditions, Signs and Symptoms
- Sepsis
- Shock, Septic
- Organic Chemicals
- Pharmaceutical Preparations
- Carboxylic Acids
- Hydroxy Acids
- Crystalloid Solutions
- Isotonic Solutions
- Solutions
- Lactates
- Saline Solution
- Sodium Lactate
Other Study ID Numbers
Other Study ID Numbers
- 2015_56
- 2017-002393-39 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.